{"denoms":[{"counts":[{"groupId":"BG000","value":"637"},{"groupId":"BG001","value":"637"},{"groupId":"BG002","value":"1274"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 Q3W for a maximum of 35 cycles (21-day cycles)","id":"BG000","title":"Pembrolizumab"},{"description":"Participants received carboplatin at target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W","id":"BG001","title":"Chemotherapy (SOC Treatment)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.9","value":"62.5"},{"groupId":"BG001","spread":"9.4","value":"63.1"},{"groupId":"BG002","spread":"9.7","value":"62.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"187"},{"groupId":"BG001","value":"185"},{"groupId":"BG002","value":"372"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"450"},{"groupId":"BG001","value":"452"},{"groupId":"BG002","value":"902"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"15"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"189"},{"groupId":"BG001","value":"187"},{"groupId":"BG002","value":"376"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"23"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"398"},{"groupId":"BG001","value":"412"},{"groupId":"BG002","value":"810"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"49"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"197"},{"groupId":"BG001","value":"192"},{"groupId":"BG002","value":"389"}],"title":"ECOG PS=0"},{"measurements":[{"groupId":"BG000","value":"439"},{"groupId":"BG001","value":"445"},{"groupId":"BG002","value":"884"}],"title":"ECOG PS=1"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"ECOG PS=2"}]}],"description":"Participants were assessed for ECOG PS: Grade 0: Fully active, able to carry on all pre-disease performance without restriction; Grade 1: Restricted in physically strenuous activity but ambulatory \\& able to carry out work of a light or sedentary nature; Grade 2: Ambulatory \\& capable of all selfcare but unable to carry out any work activities, up \\& about more than 50% of waking hours; Grade 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; Grade 4: Completely disabled, cannot carry on any selfcare, totally confined to bed or chair or Grade 5: Dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"299"},{"groupId":"BG001","value":"300"},{"groupId":"BG002","value":"599"}],"title":"TPS=≥50%"},{"measurements":[{"groupId":"BG000","value":"114"},{"groupId":"BG001","value":"105"},{"groupId":"BG002","value":"219"}],"title":"TPS=20-49%"},{"measurements":[{"groupId":"BG000","value":"224"},{"groupId":"BG001","value":"232"},{"groupId":"BG002","value":"456"}],"title":"TPS=1-19%"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"TPS=<1%"}]}],"description":"Participants were assessed for their PD-L1 tumor expression status by immunohistochemistry assay using tumor tissue from an archival or newly obtained biopsy. Participants with a tumor proportion score (TPS) were classified as follows: ≥50% = PD-L1 strongly positive; 1-49% = PD-L1 weakly positive; and \\<1% = PD-L1 negative.","paramType":"COUNT_OF_PARTICIPANTS","title":"Programmed Cell Death-Ligand 1 (PD-L1) Tumor Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"242"},{"groupId":"BG001","value":"249"},{"groupId":"BG002","value":"491"}],"title":"Squamous"},{"measurements":[{"groupId":"BG000","value":"395"},{"groupId":"BG001","value":"388"},{"groupId":"BG002","value":"783"}],"title":"Non-squamous"}]}],"description":"Participants were classified according to tumor histology: Squamous or Non-squamous. The tumor histology determined potential treatment regimen.","paramType":"COUNT_OF_PARTICIPANTS","title":"Tumor Histology","unitOfMeasure":"Participants"}],"populationDescription":"The Baseline Analysis Population consisted of all randomized participants who were alive at the time of randomization and had a Tumor Proportion Score (TPS) ≥1%."}